Clinical Trial Detail

NCT ID NCT03018080
Title Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Antoinette Tan
Indications

Her2-receptor negative breast cancer

Therapies

Paclitaxel + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST